Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 16/20 | 0.55 |
| ▸ | CA2 | P00918 | 16/20 | 0.55 |
| ▸ | CA9 | Q16790 | 16/20 | 0.55 |
| ▸ | CA1 | P00915 | 15/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 14/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394384 | 0.83 | CA12 (0.60) | CA12CA2CA9CA1CA14 | |
| SCHEMBL27619565 | 0.81 | KDM4E (0.47) | CA12CA2CA9CA1CA14 | |
| SCHEMBL18230499 | 0.81 | KDM4E (0.47) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30050575 | 0.81 | KDM4E (0.47) | CA12CA2CA9CA1CA14 | |
| Hydrochloric Acid SCHEMBL18228076 | 0.79 | KDM4E (0.46) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30014737 | 0.78 | CA12 (0.55) | CA12CA2CA9CA1CA14 | |
| SCHEMBL29114606 | 0.77 | CA12 (0.53) | CA12CA2CA9CA1CA14 | |
| SCHEMBL13177253 | 0.76 | KDM4E (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL25839306 | 0.76 | ALDH1A1 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL28259766 | 0.75 | CA12 (0.56) | CA12CA2CA9CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670490-B1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | KRATON POLYMERS LLC (US) | 2023-01-18 | — | — | EP | claimed |
| EP-3670490-A1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | Kraton Polymers LLC (US) | 2020-06-24 | — | — | EP | claimed |
| US-20200165191-A1 | Method of Purifying Pine Chemical Compositions from Aldehydes | KRATON POLYMERS LLC (US) | 2020-05-28 | — | — | US | claimed |
| EP-3670490-B1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | KRATON POLYMERS LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| US-10822302-B2 | Method of purifying pine chemical compositions from aldehydes | KRATON POLYMERS LLC (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| EP-3670490-A1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | Kraton Polymers LLC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200165191-A1 | Method of Purifying Pine Chemical Compositions from Aldehydes | KRATON POLYMERS LLC (US) | 2020-05-28 | — | — | US | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| US-7939524-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939524-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-101677563-A | 5, 6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS INC | 2010-03-24 | — | — | CN | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2129224-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | Anadys Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | CA12 4800/4885CA2 4838/4885CA9 4776/4885 |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | CA12 4594/4885CA2 4004/4885CA9 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.